SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Regeneron Pharmaceuticals
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
3117 96 0 REGN
Emcee:  Patrick Slevin Type:  Unmoderated
Regeneron (REGN) is a biotech working in recombinant DNA technology. Until '94 it generally traded between 10 and 20 dollars until the FDA beat it up on it's treatment for Lou Gehrig's Disease. While it was trading at the $4 level at the end of '94, the former chairman of Merck(I believe) took the helm and the stock climbed back to about 11, then traded between 11 and 14. In late May, Option volume increased, news about a discovery concerning muscles was announced, and the stock has risen sharply to Friday, May 24 '96 close of 18.875.

Historically, the stock has failed around 22. Yet AMGEN has more than a 17.7% stake with warrants to increase it's stake to 20%, at 16$ per share. Could this be the time it breaks out?
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3117Assuming EUA and Roche can provide a quick test of seronegative, what would be tBiotechwantabe-yesterday
3116REGN-COV2 ANTIBODY COCKTAIL PROGRAM UPDATE IF this doesn’t get a quick EUA And Biotechwantabe-Tuesday
3115The key will be Roche diagnostic, and they are very-best!Miljenko Zuanic-Tuesday
3114Many programs, rationale is not to rush anyone. NASH will not go away! Today daMiljenko Zuanic-Tuesday
3113It's about time!CuttingEdge Bio-Tuesday
3112A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With NonalcoholiBiotechwantabe1Tuesday
3111Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragmentsBiotechwantabe-Tuesday
3110There was P1b, I post a link. Formulation issue...I agree, hard to control. WillMiljenko Zuanic-Monday
3109I presume it works in animal models, but I'm not aware of any PoC in humans.DewDiligence_on_SI-Monday
3108Some posters on my Twitter stream claim the formulation issue is intractable.DewDiligence_on_SI-Monday
3107<Twenty-eight percent of patients had incomplete aggregation of GB-102 and haMiljenko Zuanic-Monday
3106Did anyone try Sunitinib to show that it does work in AMD?Miljenko Zuanic-Monday
3105GRAY IPO: investorshub.advfn.comDewDiligence_on_SI-last Friday
3104Exactly IL6 beat TNFa (https://acrabstracts.org/abstract/efficacy-and-safety-of-Felix B-last Thursday
3103Considering this is as good as keytruda but second to market, would assume regenBiotechwantabe-September 21
3102Looks at least as good to me. What are you referring to? pubmed.ncbi.nlm.nih.gCuttingEdge Bio-September 21
3101Libtayo mono Not sure how stats compares to KeytrudaBiotechwantabe-September 21
3100What do you make of the recent lily data? The lack of a dose response is quite Felix B-September 18
3099Not bad, preclinical data looks good!Miljenko Zuanic-September 14
3098Il4/13/pd-1Biotechwantabe1September 11
3097That would be very good (and quick) option.Miljenko Zuanic-August 25
3096<<(as prophylactic, few days dosing to rise nAbs level to a therapeutic onmouton29-August 24
3095This Times article from the 14th reports on the slow enrollment and says that bomouton29-August 24
3094Unless they improved on antibody mediated viro-toxicity (or viral killing)?Miljenko Zuanic-August 24
3093I'm a little confused here. How are they magically creating a formulation tCuttingEdge Bio-August 24
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):